Newsbenzinga
Dogwood Therapeutics Announces Completion Of 239-Patient Enrollment In Phase 2b Halneuron Trial For Chemotherapy Induced Neuropathic Pain; Topline Data Expected November 2026
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…